Literature DB >> 12439925

Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma.

Xiao-Zhong Guo1, Xiao-Dong Shao, Min-Pei Liu, Jian-Hua Xu, Li-Nan Ren, Jia-Jun Zhao, Hong-Yu Li, Di Wang.   

Abstract

AIM: To investigate the expression of bax, bcl-2 and bcl-xL mRNA in the tissues of normal liver and hepatocellular carcinoma (HCC), and analyze the relationship between the expression of bax, bcl-2 and bcl-xL mRNA and clinical parameters of HCC patients.
METHODS: The expression of bax, bcl-2 and bcl-xL mRNA of normal liver and HCC was measured by Northern blot. Statistical analyses were made by t test and correlation analysis.
RESULTS: A very low mRNA level was indicated at bax, bcl-2 and bcl-xL in the HCC tissues in contrast to the tissues of normal liver by Northern blot analysis. The analyses of mRNA level revealed that HCC tissues exhibited a mean 7.6-fold decrease in bax, 4.2-fold in bcl-2 and 3.5-fold in bcl-xL in comparison with normal control tissues, respectively. Positive correlation was found between bax and bcl-xL (r=0.7061, P<0.01). There was no significance between the mRNA expression of these three genes and age, gender, tumor differentiation and tumor stage of HCC patients.
CONCLUSION: The results are consistent with the fact that apoptosis rarely occurs in normal livers but increases in HCC, indicating that bcl-2 and bcl-xL may play a very important role in regulating the apoptosis of normal liver and HCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439925      PMCID: PMC4656380          DOI: 10.3748/wjg.v8.i6.1059

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs.

Authors:  Bing Xiao; Yong-Quan Shi; Yan-Qiu Zhao; Han You; Zuo-You Wang; Xian-Ling Liu; Fang Yin; Tai-Dong Qiao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer.

Authors:  H Friess; Z Lu; A Andrén-Sandberg; P Berberat; A Zimmermann; G Adler; R Schmid; M W Büchler
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

3.  bax, but not bcl-2, influences the prognosis of human pancreatic cancer.

Authors:  H Friess; Z Lu; H U Graber; A Zimmermann; G Adler; M Korc; R M Schmid; M W Büchler
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

4.  KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases.

Authors:  X Guo; H Friess; H U Graber; M Kashiwagi; A Zimmermann; M Korc; M W Büchler
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

5.  Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis.

Authors:  S Tanaka; J R Wands
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

Review 6.  Apoptosis in the pathogenesis and treatment of disease.

Authors:  C B Thompson
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

Review 7.  Apoptosis and hepatobiliary disease.

Authors:  T Patel; G J Gores
Journal:  Hepatology       Date:  1995-06       Impact factor: 17.425

8.  Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression.

Authors:  H Friess; Y Yamanaka; M Büchler; H G Berger; M S Kobrin; R L Baldwin; M Korc
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

Review 9.  Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist.

Authors:  F G Que; G J Gores
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

10.  Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival.

Authors:  Y Soini; N Virkajärvi; V P Lehto; P Pääkkö
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

View more
  23 in total

1.  Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.

Authors:  Brian I Carr; Aldo Cavallini; Catia Lippolis; Rosalba D'Alessandro; Caterina Messa; Maria G Refolo; Angela Tafaro
Journal:  J Cell Physiol       Date:  2013-02       Impact factor: 6.384

2.  Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancer.

Authors:  Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Lahousse; Hu-Hua Hong; Tai-Vu Ton; Tiwanda Masinde; Scott S Auerbach; Kevin Gerrish; Pierre R Bushel; Keith R Shockley; Shyamal D Peddada; Robert C Sills
Journal:  Toxicol Pathol       Date:  2011-05-13       Impact factor: 1.902

3.  Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p.

Authors:  Yong Wang; Baocun Sun; Huizhi Sun; Xiulan Zhao; Xudong Wang; Nan Zhao; Yanhui Zhang; Yanlei Li; Qiang Gu; Fang Liu; Bing Shao; Jindan An
Journal:  Tumour Biol       Date:  2016-02-18

4.  Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα.

Authors:  George G Chen; Jackie Leung; Nian Ci Liang; Li Li; Kefeng Wu; Ursula P F Chan; Billy C S Leung; Mingyue Li; Jing Du; Yi Feng Deng; Xianling Gong; Yingnian Lv; Ernest C W Chak; Paul B S Lai
Journal:  Invest New Drugs       Date:  2012-01-07       Impact factor: 3.850

5.  Isolation of a novel member of small G protein superfamily and its expression in colon cancer.

Authors:  Wei Yan; Wen-Liang Wang; Feng Zhu; Sheng-Quan Chen; Qing-Long Li; Li Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  SEC61G plays an oncogenic role in hepatocellular carcinoma cells.

Authors:  Huijie Gao; Weibo Niu; Zhaobin He; Chao Gao; Cheng Peng; Jun Niu
Journal:  Cell Cycle       Date:  2020-11-10       Impact factor: 4.534

7.  MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.

Authors:  Laura Gramantieri; Francesca Fornari; Manuela Ferracin; Angelo Veronese; Silvia Sabbioni; George Adrian Calin; Gian Luca Grazi; Carlo Maria Croce; Luigi Bolondi; Massimo Negrini
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 8.  MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Authors:  E Callegari; L Gramantieri; M Domenicali; L D'Abundo; S Sabbioni; M Negrini
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

9.  Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand.

Authors:  Liu-Qin Yang; Dian-Chun Fang; Rong-Quan Wang; Shi-Ming Yang
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

10.  Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signaling pathways.

Authors:  Youxing Li; Qi Zhang; Yin Liu; Zhen Luo; Lei Kang; Jing Qu; Weiyong Liu; Xueshan Xia; Yingle Liu; Kailang Wu; Jianguo Wu
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.